Skip to main content
Doctor Ali Roghanian

Dr Ali Roghanian

Associate Professor

Research interests

  • Cancer immunotherapy
  • Monoclonal antibodies
  • Immunoinhibitory receptors

More research

Accepting applications from PhD students.

Connect with Ali


"In the past decade, novel cancer immunotherapy strategies have contributed to the successful treatment of many end-stage cancer patients; yet we are just at the beginning of the road in curing all cancer (sub-)types. Hence, a better understanding of the fundamental interactions between the immune system and malignant cells is required to help achieve this goal."

As a cancer immunotherapy researcher, Dr Ali Roghanian is interested in studying tumour-mediated immunosuppression and the application of targeted therapies to promote an effective anti-tumour immunity. To achieve this, the group is using innovative technologies, including a combination of advanced preclinical models of human cancers (e.g., PDX, CDX, humanized) and complementary platforms (e.g., syngeneic models, cell cultures), and novel reagents (e.g., monoclonal antibodies).